Document and Entity Information
Document and Entity Information - shares | 3 Months Ended | |
Mar. 31, 2018 | May 01, 2018 | |
Document and Entity Information | ||
Entity Registrant Name | GENOCEA BIOSCIENCES, INC. | |
Entity Central Index Key | 1,457,612 | |
Document Type | 10-Q | |
Document Period End Date | Mar. 31, 2018 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Entity Current Reporting Status | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Common Stock, Shares Outstanding | 86,583,843 | |
Document Fiscal Year Focus | 2,018 | |
Document Fiscal Period Focus | Q1 |
Condensed Balance Sheets
Condensed Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2018 | Dec. 31, 2017 |
Current assets: | ||
Cash and cash equivalents | $ 51,179 | $ 12,273 |
Prepaid expenses and other current assets | 1,378 | 808 |
Total current assets | 52,557 | 13,081 |
Property and equipment, net | 3,172 | 3,460 |
Restricted cash | 316 | 316 |
Other non-current assets | 419 | 631 |
Total assets | 56,464 | 17,488 |
Current liabilities: | ||
Accounts payable | 2,094 | 3,516 |
Accrued expenses and other current liabilities | 4,427 | 5,604 |
Current portion of long-term debt | 0 | 6,659 |
Total current liabilities | 6,521 | 15,779 |
Non-current liabilities: | ||
Warrant liability | 21,414 | 0 |
Long-term debt | 13,874 | 7,652 |
Other non-current liabilities | 87 | 107 |
Total liabilities | 41,896 | 23,538 |
Commitments and contingencies (Note 6) | ||
Stockholders’ equity (deficit): | ||
Preferred stock | 702 | 0 |
Common stock | 83 | 29 |
Additional paid-in-capital | 293,866 | 258,114 |
Accumulated deficit | (280,083) | (264,193) |
Total stockholders’ equity (deficit) | 14,568 | (6,050) |
Total liabilities and stockholders’ equity | $ 56,464 | $ 17,488 |
Condensed Statements of Operati
Condensed Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | |
Operating expenses: | ||
Research and development | $ 7,275 | $ 9,742 |
General and administrative | 3,109 | 3,634 |
Total operating expenses | 10,384 | 13,376 |
Loss from operations | (10,384) | (13,376) |
Other expense: | ||
Other expense | (5,298) | 0 |
Interest expense, net | (208) | (359) |
Total other expense | (5,506) | (359) |
Net loss | (15,890) | (13,735) |
Unrealized loss on available-for-sale securities | 0 | (3) |
Comprehensive loss | $ (15,890) | $ (13,738) |
Net loss per share - basic and diluted (in dollars per share) | $ (0.22) | $ (0.48) |
Weighted-average number of common shares used in computing net loss per share (in shares) | 71,238 | 28,496 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | |
Operating activities | ||
Net loss | $ (15,890) | $ (13,735) |
Adjustments to reconcile net loss to net cash used in operating activities | ||
Depreciation and amortization | 270 | 449 |
Stock-based compensation | 644 | 1,021 |
Allocation of proceeds to transaction expenses | 2,115 | 0 |
Change in fair value of warrants liability | 3,183 | 0 |
Gain on sale of equipment | (38) | 0 |
Non-cash interest expense | 98 | 127 |
Changes in operating assets and liabilities | (3,515) | (2,521) |
Net cash used in operating activities | (13,133) | (14,659) |
Investing activities | ||
Purchases of property and equipment | 0 | (282) |
Proceeds from sale of equipment | 56 | 0 |
Proceeds from maturities of investments | 0 | 21,552 |
Purchases of investments | 0 | (155) |
Net cash provided by investing activities | 56 | 21,115 |
Financing activities | ||
Proceeds from underwritten public offering, net of issuance costs | 52,538 | 246 |
Payment of deferred financing costs | (20) | |
Repayment of long-term debt | (535) | 0 |
Proceeds from exercise of stock options | 0 | 12 |
Net cash provided by financing activities | 51,983 | 258 |
Net increase in cash and cash equivalents | 38,906 | 6,714 |
Cash, cash equivalents and restricted cash at beginning of period | 12,589 | 27,424 |
Cash, cash equivalents and restricted cash at end of period | 51,495 | 34,138 |
Supplemental cash flow information | ||
Cash paid for interest | 242 | 308 |
Property and equipment included in accounts payable and accrued expenses | $ 0 | $ 77 |
Organization and operations
Organization and operations | 3 Months Ended |
Mar. 31, 2018 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Organization and operations | Organization and operations The Company Genocea Biosciences, Inc. (the “Company”) is a biopharmaceutical company that was incorporated in Delaware on August 16, 2006 and has a principal place of business in Cambridge, Massachusetts. The Company seeks to discover and develop novel cancer vaccines through its AnTigen Lead Acquisition System ("ATLAS"TM) proprietary discovery platform. The ATLAS platform is designed to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify neoantigens and antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The Company believes that using ATLAS to identify neoantigens and antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the Company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of the Company’s research programs and product candidates in active development are at the preclinical stage. The Company's most advanced program in active development is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program leverages ATLAS to identify patient neoantigens, or newly formed antigens unique to each patient, that are associated with that individual's tumor. The Company is also exploring partnering opportunities in the development of cancer vaccines targeting tumor-associated antigens and a vaccine targeting cancers caused by Epstein-Barr Virus ("EBV"). The Company has one non-active Phase 3-ready product candidate, GEN-003, an investigational immunotherapy for the treatment of genital herpes. In September 2017, the Company announced it was exploring strategic alternatives for GEN-003. Consequently, substantially all GEN-003 spending and activities were ceased and the Company reduced its workforce by approximately 40 percent . The Company is devoting substantially all of its efforts to product research and development, initial market development, and raising capital. The Company has not generated any product revenue related to its primary business purpose to date and is subject to a number of risks similar to those of other preclinical stage companies, including dependence on key individuals, competition from other companies, the need and related uncertainty associated to the development of commercially viable products, and the need to obtain adequate additional financing to fund the development of its product candidates. The Company is also subject to a number of risks similar to other companies in the life sciences industry, including the uncertainty of success of its preclinical and clinical trials, regulatory approval of products, uncertainty of market acceptance of products, competition from substitute products and larger companies, the need to obtain additional financing, compliance with government regulations, protection of proprietary technology, dependence on third parties, product liability, and dependence on key individuals. The Company anticipates that it will continue to incur significant operating losses for the next several years as it continues to develop its product candidates. Liquidity As of March 31, 2018 , the Company had an accumulated deficit of approximately $280.1 million . The Company had cash and cash equivalents of $51.2 million at March 31, 2018 . The Company expects that cash and cash equivalents as of March 31, 2018 , together with the $2.9 million of net proceeds received in April 2018 under the Company's at the market offering program, are sufficient to support operating expenses and capital expenditure requirements into the fourth quarter of 2019. |
Summary of significant accounti
Summary of significant accounting policies | 3 Months Ended |
Mar. 31, 2018 | |
Accounting Policies [Abstract] | |
Summary of significant accounting policies | Summary of significant accounting policies Basis of presentation and use of estimates The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions of Form 10-Q and Article 10 of Regulation S-X. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). Certain information and footnote disclosures normally included in the Company’s annual financial statements have been condensed or omitted. These interim condensed financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Company’s financial position as of March 31, 2018 and results of operations for the three months ended March 31, 2018 and 2017 . The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2017 and the notes thereto which are included in the Company’s Annual Report on Form 10-K, as filed with the SEC on February 16, 2018. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, the Company’s management evaluates its estimates, which include, but are not limited to, estimates related to prepaid and accrued research and development expenses, stock-based compensation expense and reported amounts of revenues and expenses during the reported period. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions. Fair value of financial instruments The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. ASC Topic 820, Fair Value Measurement and Disclosures , established a hierarchy of inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the financial instrument based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the financial instrument and are developed based on the best information available under the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported or disclosed fair value of the financial instruments and is not a measure of the investment credit quality. Fair value measurements are classified and disclosed in one of the following three categories: • Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. • Level 2—Valuations based on quoted prices for similar assets or liabilities in markets that are not active or for which all significant inputs are observable, either directly or indirectly. • Level 3—Valuations that require inputs that reflect the Company’s own assumptions that are both significant to the fair value measurement and unobservable. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Financial instruments measured at fair value on a recurring basis include cash equivalents (Note 3) and liability-classified common stock warrants (Note 7). The Company is also required to disclose the fair value of financial instruments not carried at fair value. The fair value of the Company’s debt (Note 5) is determined using current applicable rates for similar instruments as of the balance sheet dates and an assessment of the credit rating of the Company. The carrying value of the Company’s debt approximates fair value because the Company’s interest rate yield is near current market rates for comparable debt instruments. The Company’s debt is considered a Level 3 liability within the fair value hierarchy. For the three months ended March 31, 2018 , there were no transfers among Level 1, Level 2, or Level 3 categories. Additionally, there were no changes to the valuation methods utilized by the Company during the three months ended March 31, 2018, other than those related to the liability-classified common stock warrants described in Note 7. The remainder of the Company's significant accounting policies are described in its Annual Report filed on Form 10-K for the year ended December 31, 2017, filed with the Securities and Exchange Commission on February 16, 2018. Recently adopted accounting standards Standard Description Effect on the financial statements ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) In May 2014, the FASB issued new revenue guidance under ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). The standard replaces existing revenue recognition standards and significantly expand the disclosure requirements for revenue arrangements. It may be adopted either retrospectively or on a modified retrospective basis to new contracts and existing contracts with remaining performance obligations as of the effective date. ASU No. 2014-09 is effective for annual reporting periods, and interim periods therein, beginning after December 15, 2017. The Company adopted ASU No. 2014-09 as of January 1, 2018. The adoption of ASU No. 2014-09 did not impact the Company's financial statements as the Company does not currently have any contracts with customers. ASU No. 2016-15, Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments In August 2016 the FASB issued ASU No. 2016-15, Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments (“ASU No. 2016-15”). This guidance addresses the presentation and classification of certain cash receipts and cash payments in the statement of cash flows. The standard is effective for annual periods beginning after December 15, 2017 and for interim periods within those fiscal years. Early adoption is permitted. The Company adopted ASU No. 2016-15 effective January 1, 2018. The adoption of ASU No. 2016-15 did not have a material impact on the Company’s financial statements. ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash In November 2016, the FASB issued ASU 2016-18, which requires additional disclosures related to restricted cash. The new standard requires that amounts generally described as restricted cash and restricted cash equivalents be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. ASU No. 2016-18 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. The Company adopted the standard on January 1, 2018 and reclassified $0.3 million of restricted cash to be included with cash and cash equivalents on the statement of cash flows. ASU No. 2017-09, Compensation-Stock Compensation (Topic 718) In May 2017, the FASB issued ASU No. 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting (“ASU No. 2017-09”). This update clarifies the changes to terms or conditions of a share-based payment award that require an entity to apply modification accounting. ASU No. 2017-09 is effective for annual reporting periods, and interim periods therein, beginning after December 15, 2017. Early application is permitted and prospective application is required. The Company adopted ASU No. 2017-09 effective January 1, 2018. The adoption of ASU No. 2017-09 did not have a material impact on the Company’s financial statements. Recently issued accounting standards Standard Description Effect on the financial statements ASU No. 2016-02, Leases (Topic 842) In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which replaces the existing lease accounting standards. The new standard requires a dual approach for lessee accounting under which a lessee would account for leases as finance (also referred to as capital) leases or operating leases. Both finance leases and operating leases will result in the lessee recognizing a right-of-use asset and corresponding lease liability. For finance leases the lessee would recognize interest expense and amortization of the right-of-use asset and for operating leases the lessee would recognize straight-line total lease expense. ASU No. 2016-02 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. The Company generally does not finance purchases of equipment but it does lease office and lab facilities. The Company is in the process of evaluating the effect that this ASU will have on its consolidated financial statements and related disclosures |
Cash, cash equivalents and inve
Cash, cash equivalents and investments | 3 Months Ended |
Mar. 31, 2018 | |
Cash and Cash Equivalents [Abstract] | |
Cash and cash equivalents | The following table presents the Company's financial instruments that were measured at fair value on a recurring basis by level in accordance with the hierarchy defined in Note 2 (in thousands): Quoted prices in active markets Significant other observable inputs Significant unobservable inputs Total (Level 1) (Level 2) (Level 3) March 31, 2018 Assets: Money market funds, included in cash equivalents $ 50,977 $ 50,977 $ — $ — Total assets $ 50,977 $ 50,977 $ — $ — Liabilities: Common stock warrant liabilities $ 21,414 $ — $ — $ 21,414 Total liabilities $ 21,414 $ — $ — $ 21,414 December 31, 2017 Assets: Money market funds, included in cash equivalents $ 11,528 $ 11,528 $ — $ — Total assets $ 11,528 $ 11,528 $ — $ — Cash equivalents have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third party pricing services or other market observable data. The pricing services utilize industry standard valuation models, including both income and market based approaches and observable market inputs to determine value. The Company validates the prices provided by its third party pricing services by reviewing their pricing methods and obtaining market values from other pricing sources. After completing its validation procedures, the Company did not adjust any fair value measurements provided by the pricing services as of March 31, 2018 and December 31, 2017 . As of March 31, 2018 and December 31, 2017 , cash and cash equivalents were comprised of funds in depository and money market accounts. In connection with an underwritten public offering of common and preferred stock in January 2018 (see Note 7), the Company issued Class A warrants (the “Warrants”) to purchase shares of the Company’s common stock. The Warrant liabilities were recorded at their fair value on the date of issuance and are remeasured as of any Warrant exercise date and at the end of the reporting period, with changes in fair value recognized as income (decrease in fair value) or expense (increase in fair value) in other income (expense) in the statements of operations. As of the issuance dates of the Warrants, and March 31, 2018, the Company utilized an option-based methodology to value the Warrants combined with a multi-scenario model, specifically a Monte Carlo simulation, in order to model the future movement of the stock price throughout the term of the Warrants. In addition, the valuation model includes the probability of the Company being acquired during each annual period within the Warrant term, as an acquisition event can potentially impact the settlement of the Warrants. The assumptions used in calculating the estimated fair value of the Warrants represent the Company’s best estimates and include probabilities of settlement scenarios, future changes in the Company’s stock price, risk-free interest rates and volatility. The estimates are based, in part, on subjective assumptions and could differ materially in the future. The following table details the assumptions used in the Monte Carlo simulation models used to estimate the fair value of the Warrants at issuance and as of March 31, 2018: Issuance Date March 31, 2018 Stock price $ 0.89 $ 1.05 Volatility 111.5 % 109.7 % Remaining term (years) 5 4.7938356164 Expected dividend yield — % — % Risk-free rate 2.4% - 2.5% 2.5 % Range of annual acquisition event probability 0.0% - 30.0% 0.0% - 30.0% The following table reflects the change in the Company’s Level 3 Warrant liabilities from issuance through March 31, 2018: Common Stock Warrant Liabilities Issuance of Warrants $ 18,231 Change in fair value 3,183 Balance at March 31, 2018 $ 21,414 In connection with the underwritten public offering, the Company also granted the underwriters a 30-day option to purchase additional shares of common stock and/or additional Warrants (the "Overallotment Option"). The Company’s Overallotment Option is also a Level 3 liability. The assumptions used to determine the fair value are described in Note 7. The following table reflects the change in the fair value of the Overallotment Option liability from issuance through March 31, 2018: Overallotment Option Liability Issuance of Overallotment Option $ 2,441 Change in fair value 194 Exercise of Overallotment Option (877 ) Expiration of Overallotment Option (1,758 ) Balance at March 31, 2018 $ — |
Accrued expenses and other curr
Accrued expenses and other current liabilities | 3 Months Ended |
Mar. 31, 2018 | |
Payables and Accruals [Abstract] | |
Accrued expenses and other current liabilities | Accrued expenses and other current liabilities Accrued expenses and other current liabilities consisted of the following (in thousands): March 31, December 31, 2018 2017 Research and development costs $ 2,860 $ 2,886 Restructuring costs — 44 Payroll and employee-related costs 915 1,830 Other current liabilities 652 844 Total $ 4,427 $ 5,604 |
Long-term debt
Long-term debt | 3 Months Ended |
Mar. 31, 2018 | |
Debt Disclosure [Abstract] | |
Long-term debt | Long-term debt On April 24, 2018 (the “Closing Date”), the Company entered into an amended and restated loan and security agreement (the “2018 Loan Agreement”) with Hercules Capital, Inc. (f/k/a Hercules Technology Growth Capital, Inc.) (“Hercules”), which provided up to $14.0 million in debt financing in the form of a term loan funded on the Closing Date (the “ 2018 Term Loan”). The 2018 Loan Agreement amended and restated the Company’s loan and security agreement (as amended, the “2014 Loan Agreement”) with Hercules, which had provided up to $27.0 million in debt financing (the “ 2014 Term Loan”). The 2018 Term Loan will mature on May 1, 2021 and accrues interest at a floating rate per annum equal to the greater of (i) 7.75% or (ii) the sum of 7.75% plus the prime rate minus 5.0% . The 2018 Loan Agreement provides for interest-only payments until June 1, 2019, which may be extended to December 1, 2019 if certain performance milestones are met before May 31, 2019 and no event of default has occurred or is continuing. Interest-only payments may be further extended to June 1, 2020 if certain additional performance milestones are met before November 30, 2019. Thereafter, amortization payments will be payable monthly in equal installments of principal and interest (subject to recalculation upon a change in prime rates) upon expiration of the interest only period through maturity. The 2018 Term Loan may be prepaid in whole or in part upon seven business days’ prior written notice to Hercules, subject to a prepayment charge of 3.0% , if such advance is prepaid in any of the first twelve months following the Closing Date, 2.0% , if such advance is prepaid after twelve months following the Closing Date but on or prior to 24 months following the Closing Date, and 1.0% thereafter. The Company is also obligated to pay an end of term charge in connection with the 2014 Loan Agreement of 4.95% of the term loan advances under the 2014 Loan Agreement on January 1, 2019 and an additional end of term charge of 6.70% of the Term Loan when the Term Loan is repaid (the “End of Term Charges”). The 2018 Term Loan is secured by a lien on substantially all of the assets of the Company, other than intellectual property, provided that such lien on substantially all assets includes any rights to payments and proceeds from the sale, licensing or disposition of intellectual property. The Loan Agreement contains non-financial covenants and representations, including a financial reporting covenant, and limitations on dividends, indebtedness, collateral, investments, distributions, transfers, mergers or acquisitions, taxes, corporate changes, deposit accounts, and subsidiaries. There are no financial covenants. The Company reclassified the principal outstanding to long-term at March 31, 2018 in accordance with ASC 470-10-45-14, as the negotiations were ongoing as of March 31, 2018 and the amendment was executed on April 24, 2018. Under the provisions of the 2014 Loan Agreement and the 2018 Loan Agreement, the Company has also entered into account control agreements ("ACAs") with Hercules and certain of the Company's financial institutions in which cash, cash equivalents, and investments are held. These ACAs grant Hercules a perfected first priority security interest in the subject accounts. The ACAs do not restrict the Company's ability to utilize cash, cash equivalents, or investments to fund operations and capital expenditures unless there is an event of default and Hercules activates its rights under the ACAs. The 2018 Loan Agreement contains a material adverse effect ("Material Adverse Effect") provision that requires all material adverse effects to be reported under the financial reporting covenant. Loan advances are subject to a representation that no event that has had or could reasonably be expected to have a Material Adverse Effect has occurred and is continuing. Under the Loan Agreement, a Material Adverse Effect means a material adverse effect upon: (i) the business, operations, properties, assets or condition (financial or otherwise) of the Company; or (ii) the ability of the Company to perform the secured obligations in accordance with the terms of the loan documents, or the ability of agent or lender to enforce any of its rights or remedies with respect to the secured obligations; or (iii) the collateral or agent’s liens on the collateral or the priority of such liens. Any event that has a Material Adverse Effect or would reasonably be expected to have a Material Adverse Effect is an event of default under the Loan Agreement and repayment of amounts due under the Loan Agreement may be accelerated by Hercules under the same terms as an event of default. Events of default under the Loan Agreement include failure to make any payments of principal or interest as due on any outstanding indebtedness, breach of any covenant, any false or misleading representations or warranties, insolvency or bankruptcy, any attachment or judgment on the Company’s assets of at least $100 thousand , or the occurrence of any material default of the Company involving indebtedness in excess of $100 thousand . If an event of default occurs, repayment of all amounts due under the Loan Agreement may be accelerated by Hercules, including the applicable prepayment charge. The 2018 Term Loan is automatically redeemable upon a change in control. The Company must prepay the outstanding principal and any accrued and unpaid interest through the prepayment date and the applicable prepayment charge. If a change in control occurs, repayment of amounts due under the Loan Agreement may be accelerated by Hercules. The Company believes acceleration of the repayment of amounts outstanding under the loan is remote, and therefore the debt balance is classified according to the contractual payment terms at March 31, 2018. In connection with the 2014 Term Loan, the Company issued a common stock warrant to Hercules on November 20, 2014 (the “First Warrant”). The First Warrant is exercisable for 73,725 shares of the Company’s Common Stock (equal to $607,500 divided by the exercise price of $8.24 ). The exercise price and the number of shares are subject to adjustment upon a merger event, reclassification of the shares of Common Stock, subdivision or combination of the shares of Common Stock or certain dividends payments. The First Warrant is exercisable until November 20, 2019 and will be exercised automatically on a net issuance basis if not exercised prior to the expiration date and if the then-current fair market value of one share of Common Stock is greater than the exercise price then in effect. The First Warrant has been classified as equity for all periods it has been outstanding. In connection with the 2018 Loan Agreement, the Company issued a common stock warrant to Hercules on April 24, 2018 (the "Second Warrant" and together with the First Warrant, the “Warrants”). The Second Warrant is exercisable for 329,411 shares of the Company’s common stock. The exercise price and the number of shares are subject to adjustment upon a merger event, reclassification of the shares of common stock, subdivision or combination of the shares of common stock or certain dividends payments. The Second Warrant is exercisable until April 24, 2023 and will be exercised automatically on a net issuance basis if not exercised prior to the expiration date and if the then-current fair market value of one share of common stock is greater than the exercise price then in effect. Contemporaneously with the 2018 Loan Agreement, the Company also entered into an amendment to the equity rights letter agreement, dated November 20, 2014 (the “Amended Equity Rights Letter Agreement”). Pursuant to the Amended Equity Rights Letter Agreement, the Company issued to Hercules 223,463 shares of the Company’s Common Stock for an aggregate purchase price of approximately $2.0 million at a price per share equal to the closing price of the Company’s Common Stock as reported on The Nasdaq Global Market on November 19, 2014. The shares will be subject to resale limitations and may be resold only pursuant to an effective registration statement or an exemption from registration. Additionally, under the Amended Equity Rights Letter Agreement, Hercules has the right to participate in any one or more subsequent private placement equity financings of up to $2.0 million on the same terms and conditions as purchases by the other investors in each subsequent equity financing. The Amended Equity Rights Letter Agreement, and all rights and obligations thereunder, will terminate upon the earlier of (1) such time when Hercules has purchased $2.0 million of subsequent equity financing securities in the aggregate and (2) the later of (a) the repayment of all indebtedness under the Loan Agreement and (b) the expiration or termination of the exercise period for the warrant issued in connection with the Loan Agreement. The Company allocated $36 thousand of financing costs to additional paid-in capital for issuance fees that were reimbursed to Hercules. The Company incurred $0.3 million in debt financing costs related to the first amendment to the 2014 Loan Agreement (the "First Amendment"), which was recorded as a debt discount and will be amortized over the remaining loan term. In connection with the issuance of the 2014 Term Loan, the Company incurred $0.1 million of financing costs and also reimbursed Hercules $0.2 million for debt financing costs, which has been recorded as a debt discount and will be amortized over the remaining loan term. The End of Term Charges are amortized ratably over the term loan period based upon the outstanding debt and the increase in the amount of End of Term Charges due to the additional borrowing from the First Amendment is being amortized from the First Amendment date through maturity. The debt discount is being amortized to interest expense over the life of the 2014 Term Loan using the effective interest method. At March 31, 2018, the 2014 Term Loan bears an effective interest rate of 10.2% . As of March 31, 2018 and December 31, 2017, the Company had outstanding borrowings under the 2014 Term Loan of $13.9 million and $14.3 million , respectively. Interest expense related to the 2014 Term Loan was $0.3 million and $0.4 million , for the three months ended March 31, 2018 and 2017, respectively. Future principal payments, including the End of Term Charge, on the 2014 Term Loan are as follows (in thousands): March 31, 2018 2018 $ 3,309 2019 10,848 Total $ 14,157 |
Commitments and contingencies
Commitments and contingencies | 3 Months Ended |
Mar. 31, 2018 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and contingencies | Commitments and contingencies Lease commitments In May 2016, the Company entered into a lease amendment (the "2016 Lease") for office and laboratory space currently occupied under an original lease that commenced in March 2014 and was set to expire in February 2017 (the "2014 Lease"). The 2016 Lease extended the 2014 Lease by three years through February 2020. In June 2015, the Company signed a second operating lease (the "2015 Lease") for office space in the same building as the 2014 Lease. In August 2016, the Company exercised a three -year renewal option extending the 2015 Lease to February 2020. The combined minimum future lease payments under both the 2016 Lease and the 2015 Lease are as follows (in thousands): March 31, 2018 2018 1,209 2019 1,637 2020 274 Total $ 3,120 At March 31, 2018 and December 31, 2017 , the Company has an outstanding letter of credit of $316 thousand with a financial institution related to a security deposit for the 2016 Lease, which is secured by cash on deposit and expires on February 29, 2020. An additional unsecured deposit was required for the 2015 Lease. Litigation On October 31, 2017, a putative class action complaint was filed in the U.S. District Court for the District of Massachusetts (the “District of Massachusetts” or the "Court”), naming the Company, Chief Executive Officer William D. Clark, and Chief Financial Officer Jonathan Poole as defendants. The complaint alleges violations of the Securities Exchange Act of 1934 and Rule 10b-5 in connection with disclosures made in and subsequent to the Company’s Quarterly Report on Form 10-Q for the period ending March 31, 2017, filed with the SEC on May 5, 2017, and the Company’s announcement of a strategic shift to immuno-oncology on September 25, 2017. The plaintiff sought to represent a class of shareholders who purchased or otherwise acquired the Company’s securities between May 5, 2017 and September 25, 2017. The complaint sought unspecified damages and costs. On November 3, 2017, another purported Company shareholder filed a substantially identical complaint in the District of Massachusetts. On December 15, 2017, a purported Company shareholder filed a third complaint in the District of Massachusetts, substantially the same as the previous two, but alleging a class period beginning on August 4, 2016 and ending on September 25, 2017. The District of Massachusetts designated all three complaints as related, and entered an order in each action recognizing that the defendants are not obligated to respond to the initial complaint filed in any of the three actions. Per the procedures set forth by federal securities laws, applications for appointment of lead plaintiff(s) and lead counsel in the three actions were due to the Court on January 2, 2018. Three applications for lead plaintiff and lead counsel were submitted to the Court on that date; one of the three movants subsequently withdrew their application. The Court held a hearing on the two remaining motions for lead plaintiff(s) and lead counsel on January 31, 2018. The Court consolidated the three actions into one case, under the docket number Civil Action No. 17-cv-12137-PBS, U.S. District Court (Mass.), and took the motions for lead plaintiff(s) and counsel under advisement. Counsel for both lead plaintiff movants told the Court that they intended to file an amended complaint in the consolidated action, if appointed. On February 12, 2018, the Court appointed the Genocea Investor Group (a group of five purported shareholders) as lead plaintiff, and appointed Scott+Scott LLP, Levi & Korsinsky LLP, and Block & Leviton LLP as lead counsel. On February 14, 2018, the parties submitted a stipulation proposing a briefing schedule with the following deadlines: filing of an amended complaint by the lead plaintiffs and counsel due March 29, 2018; filing of an answer or motion to dismiss by defendants on May 14, 2018; filing of any opposition by plaintiffs to a motion to dismiss on June 28, 2018; and filing of any reply by defendants in support of a motion to dismiss on July 30, 2018. On March 30, 2018, counsel for the lead plaintiff filed an amended complaint in the District of Massachusetts, adding Seth V. Hetherington, former Chief Medical Officer, to the original named defendants. The defendants anticipate filing a motion to dismiss by May 14, 2018. On January 31, 2018, a putative shareholder derivative action was filed in the U.S. District Court for the District of Delaware, naming certain of the Company’s officers and directors as defendants (including certain former directors), and naming the Company as a nominal defendant. The complaint alleges violations of the Securities Exchange Act of 1934 and Rule 14a-9 in connection with disclosures made in the Company’s Schedule 14A Proxy Statement, filed with the SEC on April 21, 2017. The complaint also alleges claims for breach of fiduciary duty, unjust enrichment, and waste of corporate assets. On May 1, 2018, the parties filed a joint stipulation and proposed order agreeing to stay the action until, inter alia , the entry of an order granting or denying any motion to dismiss the action in the District of Massachusetts, and on May 9, 2018, the court entered the joint stipulation agreeing to stay the action. The Company is unable at this time to determine whether the outcome of any of the litigation would have a material impact on its results of operations, financial condition or cash flows. The Company does not have contingency reserves established for any litigation liabilities. |
Stockholders' equity
Stockholders' equity | 3 Months Ended |
Mar. 31, 2018 | |
Equity [Abstract] | |
Stockholders' equity | Stockholders' equity As of March 31, 2018 , the Company authorized 175,000,000 shares of common stock at $0.001 par value per share and 25,000,000 shares of preferred stock at $0.001 par value per share. As of March 31, 2018 , 83,057,643 shares of common stock and 1,635 shares of preferred stock were issued and outstanding. As of December 31, 2017 , 28,734,898 shares of common stock were issued and outstanding and no shares of preferred stock were issued and outstanding. Underwritten public offering On January 17, 2018, the Company entered into two underwriting agreements, the first relating to the underwritten public offering of 53,365,000 shares of the Company’s common stock, par value $0.001 per share, and accompanying Warrants to purchase up to 26,682,500 shares of common stock, at a combined price to the public of $1.00 per share, for gross proceeds of approximately $53.4 million (the “Common Stock Offering”) and the second relating to the underwritten public offering of 1,635 shares of the Company’s Series A convertible preferred stock, par value $0.001 per share, which are convertible into 1,635,000 shares of common stock, and accompanying warrants to purchase up to 817,500 shares of common stock for for gross proceeds of approximately $1.6 million (the “Preferred Stock Offering,” and together with the Common Stock Offering, the “January 2018 Financing”). Under the terms of the underwriting agreement for the Common Stock Offering, the Company also granted the underwriters the Overallotment Option to purchase up to an additional 8,004,750 shares of common stock and/or additional warrants to purchase up to 4,002,375 shares of common stock. On January 19, 2018, the underwriters exercised their Overallotment Option to acquire additional warrants to purchase up to 1,438,050 shares of common stock. On February 21, 2018, the underwriters exercised their Overallotment Option to acquire an additional 957,745 shares of common stock. The Company received approximately $1.0 million in gross proceeds from the underwriter’s exercise of the Overallotment Option. Preferred Stock Each share of preferred stock is convertible at any time at the option of the holder, provided that the holder will be prohibited from converting the preferred stock into shares of common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 9.99% of the total number of shares of common stock then issued and outstanding. Each share of preferred stock is initially convertible into 1,000 shares of common stock, subject to certain adjustments upon stock dividends and stock splits. The preferred stock ranks pari passu on an as-converted to common stock basis with the common stock as to distributions of assets upon the Company’s liquidation, dissolution or winding up, whether voluntarily or involuntarily, or a “Fundamental Transaction,” as defined in the Certificate of Designation. Shares of preferred stock have no voting rights, except as required by law and except that the consent of the holders of a majority of the outstanding preferred stock is required to amend the terms of the preferred stock. The holders of preferred stock shall be entitled to receive dividends in the same form as dividends actually paid on shares of common stock when, as and if such dividends are declared and paid on shares of the common stock, on an as-if-converted-to-common stock basis. Warrants The Warrants are exercisable at any time or from time to time during the period beginning on the date of issuance and expiring on the five-year anniversary of such issuance date, at an exercise price of $1.20 per share. In the event of an “Acquisition,” defined generally to include a merger or consolidation resulting in the sale of 50% or more of the voting securities of the Company, the sale of all or substantially all of the assets or voting securities of the Company, or other change of control transaction, as defined in the Warrants, the Company will be obligated to use its best efforts to ensure that the holders of the Warrants receive new warrants from the surviving or acquiring entity (the “Acquirer”). The new warrants to purchase shares in the Acquirer shall have the same expiration date as the Warrants and a strike price that is based on the proportion of the value of the Acquiror’s stock to the Company’s common stock. If the Company is unable, despite its best efforts, to cause the Acquirer to issue new warrants in the Acquisition as described above, then, if the Company’s stockholders are to receive cash in the Acquisition, the Company will settle the Warrants in cash and if the Company’s stockholders are to receive stock in the Acquisition, the Company will issue shares of its common stock to each Warrant holder. Accounting for the January 2018 Financing Transaction In assessing the accounting for the January 2018 Financing, the Company first determined that the common and preferred stock and the Warrants represented separable freestanding financial instruments. Next, the Company determined that the Warrants should be liability classified in accordance with ASC 480, Distinguishing Liabilities from Equity (“ASC 480”), given the ability for the holders of the Warrants to redeem the Warrants for cash in certain Acquisition scenarios, as described above. As such, the Company allocated proceeds from the Common Stock Offering and Preferred Stock Offering in order to record the related Warrants at their fair value as of the date of issuance. In addition, the Company recorded the Warrants issued to the underwriters as part of the exercise of their Overallotment Option at their fair value as of the date of issuance. As the Warrants are liability-classified, the Company will remeasure the fair value of the Warrant liability at each reporting date. The Company recorded the Warrants issued in the January 2018 Financing at their estimated fair value of approximately $18.2 million as of the issuance date. The Company recorded other expense of approximately $3.2 million in the quarter ended March 31, 2018, due to the increase in the estimated fair value of the Warrants to approximately $21.4 million as of March 31, 2018 (see Note 3). In assessing the preferred stock, the Company determined that it was more equity-like in nature, which served as the basis for evaluating the other embedded features within the preferred stock. The Company determined that the conversion feature, redemption feature and other embedded features of the preferred stock did not meet the definition of derivatives and did not require separate accounting. The Company determined that the preferred stock should be classified as permanent equity as its redemption, dividends, covenants, liquidation and conversion features are more equity-like than debt-like. The Company further assessed the conversion feature of the preferred stock to determine if it was beneficial to the holder at issuance. Given the value allocated from the preferred stock to the Warrants issued in the Preferred Stock Offering, the Company determined that the effective conversion price was in the money at issuance and calculated the intrinsic value of the beneficial conversion of approximately $0.3 million . The Company recorded this amount to additional paid-in capital upon the issuance of the preferred stock. The Company determined that the Overallotment Option should be classified as a liability in accordance with ASC 480 on the basis that the Overallotment Option was exercisable for Warrants that are classified as liabilities under ASC 480. As the Overallotment Option is a traditional overallotment option that remained with the underwriters, no proceeds from the January 2018 Financing were allocated. Given the short-term duration of the Overallotment Option, the Company estimated its fair value was representative of the intrinsic value of the related Warrants, based on the estimated fair value of the Warrants at issuance and the exercise price of the Overallotment Option. The Company estimated the fair value of the Overallotment Option at the issuance to be approximately $2.4 million . Upon the partial exercise of the Overallotment Option by the underwriters, the Company reclassified a proportional amount of the Overallotment Option liability of $0.9 million to the Warrant liability, to reflect the fair value of the Warrants issued to the underwriters. Upon expiration of the Overallotment Option, the Company recognized the $1.6 million liability balance as expense accordingly. In connection with the January 2018 Financing, the Company incurred approximately $4.0 million of issuance costs. The Company allocated approximately $2.6 million of the issuance costs to the common and preferred stock, and recorded these amounts against the proceeds received, and approximately $1.4 million of the issuance costs to the Warrants, on the basis of the relative values assigned. As the Warrants were classified as liabilities, the Company immediately expensed the issuance costs allocated to the Warrants. At-the-market equity offering program On March 2, 2015, the Company entered into a Sales Agreement with Cowen and Company, LLC (the "Sales Agreement") to establish an at-the-market equity offering program (“ATM”) pursuant to which it was able to offer and sell up to $40 million of its common stock at prevailing market prices from time to time. On May 8, 2015, the Sales Agreement was amended to increase the offering amount under the ATM to $50 million of its common stock. Through May 9, 2018, the Company sold an aggregate of approximately 3.7 million shares under the ATM and received approximately $4.0 million in net proceeds after deducting commissions. Warrants As of March 31, 2018 and December 31, 2017 , the Company had warrants outstanding that represent the right to acquire 29,015,653 and 77,603 shares of common stock, respectively. As of March 31, 2018 , the common stock underlying the warrants consist of 28,938,050 shares of common stock reserved for issuance upon the exercise of the Warrants, 73,725 shares of common stock reserved for issuance upon the exercise of warrants issued to Hercules and 3,878 shares of common stock reserved for issuance upon the exercise of warrants issued in periods prior to the Company's initial public offering ("IPO"). |
Stock and employee benefit plan
Stock and employee benefit plans | 3 Months Ended |
Mar. 31, 2018 | |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |
Stock and employee benefit plans | Stock and employee benefit plans Stock-based compensation expense Total stock-based compensation expense is recognized for stock options and restricted stock awards granted to employees and non-employees and has been reported in the Company’s statements of operations as follows (in thousands): Three Months Ended March 31, 2018 2017 Research and development $ 141 $ 387 General and administrative 503 634 Total $ 644 $ 1,021 Stock options The following table summarizes stock option activity for employees and nonemployees (shares in thousands): Shares Weighted- Weighted- Aggregate Outstanding at December 31, 2017 4,129 $ 5.48 7.07 $ — Granted 1,826 $ 1.00 Exercised — $ — Canceled (763 ) $ 3.95 Outstanding at March 31, 2018 5,192 $ 4.13 6.8 $ 97 Exercisable at March 31, 2018 2,478 $ 5.88 4.52 $ 2 Vested or expected to vest at March 31, 2018 5,192 $ 4.13 6.8 $ 97 Restricted stock In May 2017, the Company granted an officer 47,620 units of restricted stock ("RSUs") in accordance with the 2014 Equity Incentive Plan and subject to a Restricted Stock Unit Award Agreement with the Company. On the date of grant, 7,937 RSUs vested immediately and another 23,810 RSUs were to vest on the eighteen month anniversary of the grant date, subject to the continued employment of the officer. The remaining 15,873 RSUs, which contained a performance condition of completing a material financing event on or before September 30, 2017, were canceled as the performance criterion was not achieved. Upon the resignation of the officer in March 2018, the remaining 23,810 RSUs were forfeited. Performance-based awards The Company granted stock awards to certain employees, executive officers and consultants, which contain performance-based vesting criteria. Milestone events are specific to the Company’s corporate goals, which include, but are not limited to, certain clinical development milestones, business development agreements and capital fundraising events. Stock-based compensation expense associated with these performance-based stock options is recognized if the performance conditions are considered probable of being achieved, using management’s best estimates. The Company determined that none of the performance-based milestones were probable of achievement during the three months ended March 31, 2018 , and accordingly did not recognize stock-based compensation expense for these periods. As of March 31, 2018 , there were 56,336 performance-based common stock awards outstanding for which the probability of achievement was not deemed probable. Employee stock purchase plan On February 10, 2014, the Company’s board of directors adopted the 2014 Employee Stock Purchase Plan (the “2014 ESPP”). The 2014 ESPP authorizes the initial issuance of up to a total of 200,776 shares of common stock to participating eligible employees. The 2014 ESPP provides for six-month option periods commencing on January 1 and ending June 30 and commencing July 1 and ending December 31 of each calendar year. As of March 31, 2018 , 7 shares remain for future issuance under the plan. The Company incurred stock-based compensation expense related to the 2014 ESPP of $11 thousand and $38 thousand for the three months ended March 31, 2018 and 2017 , respectively. |
Restructuring costs
Restructuring costs | 3 Months Ended |
Mar. 31, 2018 | |
Restructuring and Related Activities [Abstract] | |
Restructuring costs | Restructuring costs On September 25, 2017, the Company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines, including GEN-009. The Company also announced that it is exploring strategic alternatives for GEN-003, its Phase 3-ready investigational immunotherapy for the treatment of genital herpes. Consequently, substantially all GEN-003 spending and activities were ceased and the Company reduced its workforce by approximately 40 percent as of the quarter ended September 30, 2017. Pursuant to ASC 420, Exit or Disposal Cost Obligations, charges for employee severance, employee benefits, and contract terminations were recorded in the year ended December 31, 2017. Asset impairment charges, pursuant to ASC 360, Property, Plant, and Equipment, were also recorded in the year ended December 31, 2017 and primarily related to fixed assets specific to GEN-003 research and development activities. The following table summarizes the impact of the September 2017 restructuring activities for the year ended December 31, 2017 and three months ended March 31, 2018, along with the current liability recorded in the balance sheet as of December 31, 2017 and March 31, 2018 (in thousands): (in thousands) Charges incurred during the year ended December 31, 2017 Amount paid through December 31, 2017 Less non-cash charges during the year ended December 31, 2017 Remaining liability at December 31, 2017 Amount paid during Q1 2018 Remaining liability at March 31, 2018 Employee severance, benefits and related costs $ 1,064 $ (1,050 ) $ — $ 14 $ (14 ) $ — Contract terminations 526 526 (526 ) — Asset impairments 1,028 — (1,028 ) — — — Total $ 2,618 $ (1,050 ) $ (1,028 ) $ 540 $ (540 ) $ — |
Net loss per share attributable
Net loss per share attributable to common stockholders | 3 Months Ended |
Mar. 31, 2018 | |
Earnings Per Share [Abstract] | |
Net loss per share | Net loss per share The Company computes basic and diluted earnings (loss) per share using a methodology that gives effect to the impact of outstanding participating securities (the “two-class method”). For both the three -month periods ended March 31, 2018 and 2017 , there is no income allocation required under the two-class method or dilution attributed to weighted average shares outstanding in the calculation of diluted loss per share. The following common stock equivalents, presented on an as converted basis, were excluded from the calculation of net loss per share for the periods presented, due to their anti-dilutive effect (in thousands): Three Months Ended March 31, 2018 2017 Stock options 5,192 4,968 Warrants 29,016 78 Outstanding ESPP — 24 Total 34,208 5,070 |
Summary of significant accoun15
Summary of significant accounting policies (Policies) | 3 Months Ended |
Mar. 31, 2018 | |
Accounting Policies [Abstract] | |
Basis of presentation | Basis of presentation and use of estimates The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions of Form 10-Q and Article 10 of Regulation S-X. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). Certain information and footnote disclosures normally included in the Company’s annual financial statements have been condensed or omitted. These interim condensed financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Company’s financial position as of March 31, 2018 and results of operations for the three months ended March 31, 2018 and 2017 . The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2017 and the notes thereto which are included in the Company’s Annual Report on Form 10-K, as filed with the SEC on February 16, 2018. |
Use of estimates | The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, the Company’s management evaluates its estimates, which include, but are not limited to, estimates related to prepaid and accrued research and development expenses, stock-based compensation expense and reported amounts of revenues and expenses during the reported period. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions. |
Fair value of financial instruments | Fair value of financial instruments The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. ASC Topic 820, Fair Value Measurement and Disclosures , established a hierarchy of inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the financial instrument based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the financial instrument and are developed based on the best information available under the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported or disclosed fair value of the financial instruments and is not a measure of the investment credit quality. Fair value measurements are classified and disclosed in one of the following three categories: • Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. • Level 2—Valuations based on quoted prices for similar assets or liabilities in markets that are not active or for which all significant inputs are observable, either directly or indirectly. • Level 3—Valuations that require inputs that reflect the Company’s own assumptions that are both significant to the fair value measurement and unobservable. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Financial instruments measured at fair value on a recurring basis include cash equivalents (Note 3) and liability-classified common stock warrants (Note 7). The Company is also required to disclose the fair value of financial instruments not carried at fair value. The fair value of the Company’s debt (Note 5) is determined using current applicable rates for similar instruments as of the balance sheet dates and an assessment of the credit rating of the Company. The carrying value of the Company’s debt approximates fair value because the Company’s interest rate yield is near current market rates for comparable debt instruments. The Company’s debt is considered a Level 3 liability within the fair value hierarchy. |
Recently issued accounting standards | Recently issued accounting standards Standard Description Effect on the financial statements ASU No. 2016-02, Leases (Topic 842) In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which replaces the existing lease accounting standards. The new standard requires a dual approach for lessee accounting under which a lessee would account for leases as finance (also referred to as capital) leases or operating leases. Both finance leases and operating leases will result in the lessee recognizing a right-of-use asset and corresponding lease liability. For finance leases the lessee would recognize interest expense and amortization of the right-of-use asset and for operating leases the lessee would recognize straight-line total lease expense. ASU No. 2016-02 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. The Company generally does not finance purchases of equipment but it does lease office and lab facilities. The Company is in the process of evaluating the effect that this ASU will have on its consolidated financial statements and related disclosures |
Cash, cash equivalents and in16
Cash, cash equivalents and investments (Tables) | 3 Months Ended |
Mar. 31, 2018 | |
Cash and Cash Equivalents [Abstract] | |
Schedule of cash equivalents and investments carried at fair value | The following table presents the Company's financial instruments that were measured at fair value on a recurring basis by level in accordance with the hierarchy defined in Note 2 (in thousands): Quoted prices in active markets Significant other observable inputs Significant unobservable inputs Total (Level 1) (Level 2) (Level 3) March 31, 2018 Assets: Money market funds, included in cash equivalents $ 50,977 $ 50,977 $ — $ — Total assets $ 50,977 $ 50,977 $ — $ — Liabilities: Common stock warrant liabilities $ 21,414 $ — $ — $ 21,414 Total liabilities $ 21,414 $ — $ — $ 21,414 December 31, 2017 Assets: Money market funds, included in cash equivalents $ 11,528 $ 11,528 $ — $ — Total assets $ 11,528 $ 11,528 $ — $ — |
Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block] | The following table details the assumptions used in the Monte Carlo simulation models used to estimate the fair value of the Warrants at issuance and as of March 31, 2018: Issuance Date March 31, 2018 Stock price $ 0.89 $ 1.05 Volatility 111.5 % 109.7 % Remaining term (years) 5 4.7938356164 Expected dividend yield — % — % Risk-free rate 2.4% - 2.5% 2.5 % Range of annual acquisition event probability 0.0% - 30.0% 0.0% - 30.0% |
Accrued expenses and other cu17
Accrued expenses and other current liabilities (Tables) | 3 Months Ended |
Mar. 31, 2018 | |
Payables and Accruals [Abstract] | |
Schedule of accrued expenses and other current liabilities | Accrued expenses and other current liabilities consisted of the following (in thousands): March 31, December 31, 2018 2017 Research and development costs $ 2,860 $ 2,886 Restructuring costs — 44 Payroll and employee-related costs 915 1,830 Other current liabilities 652 844 Total $ 4,427 $ 5,604 |
Long-term debt (Tables)
Long-term debt (Tables) | 3 Months Ended |
Mar. 31, 2018 | |
Debt Disclosure [Abstract] | |
Schedule of future principal payments | March 31, 2018 2018 $ 3,309 2019 10,848 Total $ 14,157 |
Commitments and contingencies (
Commitments and contingencies (Tables) | 3 Months Ended |
Mar. 31, 2018 | |
Commitments and Contingencies Disclosure [Abstract] | |
Schedule of future minimum lease payments | The combined minimum future lease payments under both the 2016 Lease and the 2015 Lease are as follows (in thousands): March 31, 2018 2018 1,209 2019 1,637 2020 274 Total $ 3,120 |
Stock and employee benefit pl20
Stock and employee benefit plans (Tables) | 3 Months Ended |
Mar. 31, 2018 | |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |
Schedule of stock-based compensation expense for stock options granted to employees and non-employees | Total stock-based compensation expense is recognized for stock options and restricted stock awards granted to employees and non-employees and has been reported in the Company’s statements of operations as follows (in thousands): Three Months Ended March 31, 2018 2017 Research and development $ 141 $ 387 General and administrative 503 634 Total $ 644 $ 1,021 |
Schedule of stock option activity for employees and nonemployees | The following table summarizes stock option activity for employees and nonemployees (shares in thousands): Shares Weighted- Weighted- Aggregate Outstanding at December 31, 2017 4,129 $ 5.48 7.07 $ — Granted 1,826 $ 1.00 Exercised — $ — Canceled (763 ) $ 3.95 Outstanding at March 31, 2018 5,192 $ 4.13 6.8 $ 97 Exercisable at March 31, 2018 2,478 $ 5.88 4.52 $ 2 Vested or expected to vest at March 31, 2018 5,192 $ 4.13 6.8 $ 97 |
Restructuring costs (Tables)
Restructuring costs (Tables) | 3 Months Ended |
Mar. 31, 2018 | |
Restructuring and Related Activities [Abstract] | |
Summary of restructuring activities | The following table summarizes the impact of the September 2017 restructuring activities for the year ended December 31, 2017 and three months ended March 31, 2018, along with the current liability recorded in the balance sheet as of December 31, 2017 and March 31, 2018 (in thousands): (in thousands) Charges incurred during the year ended December 31, 2017 Amount paid through December 31, 2017 Less non-cash charges during the year ended December 31, 2017 Remaining liability at December 31, 2017 Amount paid during Q1 2018 Remaining liability at March 31, 2018 Employee severance, benefits and related costs $ 1,064 $ (1,050 ) $ — $ 14 $ (14 ) $ — Contract terminations 526 526 (526 ) — Asset impairments 1,028 — (1,028 ) — — — Total $ 2,618 $ (1,050 ) $ (1,028 ) $ 540 $ (540 ) $ — |
Net loss per share attributab22
Net loss per share attributable to common stockholders (Tables) | 3 Months Ended |
Mar. 31, 2018 | |
Earnings Per Share [Abstract] | |
Schedule of common stock equivalents, presented on converted basis, were excluded from calculation of net loss per share due to anti-dilutive effect | The following common stock equivalents, presented on an as converted basis, were excluded from the calculation of net loss per share for the periods presented, due to their anti-dilutive effect (in thousands): Three Months Ended March 31, 2018 2017 Stock options 5,192 4,968 Warrants 29,016 78 Outstanding ESPP — 24 Total 34,208 5,070 |
Organization and operations (De
Organization and operations (Details) - USD ($) $ in Thousands | Mar. 31, 2018 | Dec. 31, 2017 |
Restructuring Cost and Reserve [Line Items] | ||
Accumulated deficit | $ (280,083) | $ (264,193) |
Cash and cash equivalents | $ 51,179 | $ 12,273 |
Strategic alternatives for GEN-003 | ||
Restructuring Cost and Reserve [Line Items] | ||
Reduction to workforce (as a percent) | 40.00% |
Summary of significant accoun24
Summary of significant accounting policies - Narrative (Details) - USD ($) $ in Thousands | Mar. 31, 2018 | Jan. 01, 2018 | Dec. 31, 2017 |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||
Cash and cash equivalents | $ 51,179 | $ 12,273 | |
Accounting Standards Update 2016-18 | |||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||
Restricted Cash and Cash Equivalents | $ 300 | ||
Cash and cash equivalents | $ (300) |
Cash, cash equivalents and in25
Cash, cash equivalents and investments - Schedule of cash equivalents and investments carried at fair value (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands | Mar. 31, 2018 | Dec. 31, 2017 |
Assets: | ||
Total assets | $ 50,977 | $ 11,528 |
Liabilities: | ||
Common stock warrant liabilities | 21,414 | |
Total liabilities | 21,414 | |
(Level 1) | ||
Assets: | ||
Total assets | 50,977 | 11,528 |
Liabilities: | ||
Common stock warrant liabilities | 0 | |
Total liabilities | 0 | |
(Level 2) | ||
Assets: | ||
Total assets | 0 | 0 |
Liabilities: | ||
Common stock warrant liabilities | 0 | |
Total liabilities | 0 | |
(Level 3) | ||
Assets: | ||
Total assets | 0 | 0 |
Liabilities: | ||
Common stock warrant liabilities | 21,414 | |
Total liabilities | 21,414 | |
Money market funds | ||
Assets: | ||
Included in cash equivalents | 50,977 | 11,528 |
Money market funds | (Level 1) | ||
Assets: | ||
Included in cash equivalents | 50,977 | 11,528 |
Money market funds | (Level 2) | ||
Assets: | ||
Included in cash equivalents | 0 | 0 |
Money market funds | (Level 3) | ||
Assets: | ||
Included in cash equivalents | $ 0 | $ 0 |
Cash, cash equivalents and in26
Cash, cash equivalents and investments - Assumptions used in the Monte Carlo simulation models (Details) - $ / shares | 1 Months Ended | 3 Months Ended |
Jan. 31, 2018 | Mar. 31, 2018 | |
Warrants | ||
Fair Value Inputs, Liabilities, Quantitative Information [Line Items] | ||
Stock price | $ 0.89 | $ 1.05 |
Volatility | 111.50% | 109.70% |
Remaining term (years) | 5 years | 4 years 9 months 16 days |
Expected dividend yield | 0.00% | 0.00% |
Minimum [Member] | ||
Fair Value Inputs, Liabilities, Quantitative Information [Line Items] | ||
Risk-free rate | 2.45% | |
Range of annual acquisition event probability | 0.00% | 0.00% |
Maximum [Member] | ||
Fair Value Inputs, Liabilities, Quantitative Information [Line Items] | ||
Risk-free rate | 2.50% | |
Range of annual acquisition event probability | 30.00% | 3000000.00% |
Cash, cash equivalents and in27
Cash, cash equivalents and investments - Change in the Company’s Level 3 Warrant liabilities (Details) $ in Thousands | 3 Months Ended |
Mar. 31, 2018USD ($) | |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | |
Change in fair value | $ 1,600 |
Warrants | (Level 3) | |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | |
Change in fair value | 3,183 |
Balance at March 31, 2018 | $ 21,414 |
Cash, cash equivalents and in28
Cash, cash equivalents and investments - Overallotment Option (Details) - Overallotment Option $ in Thousands | 3 Months Ended |
Mar. 31, 2018USD ($) | |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | |
Change in fair value | $ 194 |
Exercise of Overallotment Option | (877) |
Expiration of Overallotment Option | (1,758) |
Balance at March 31, 2018 | $ 0 |
Accrued expenses and other cu29
Accrued expenses and other current liabilities (Details) - USD ($) $ in Thousands | Mar. 31, 2018 | Dec. 31, 2017 |
Payables and Accruals [Abstract] | ||
Research and development costs | $ 2,860 | $ 2,886 |
Payroll and employee-related costs | 915 | 1,830 |
Other current liabilities | 652 | 844 |
Total | $ 4,427 | $ 5,604 |
Long-term debt - Narrative (Det
Long-term debt - Narrative (Details) - USD ($) | Apr. 24, 2018 | Nov. 20, 2014 | Mar. 31, 2018 | Mar. 31, 2017 | Dec. 31, 2017 |
Common Stock | |||||
Long-Term Debt | |||||
Exercisable amount (in shares) | 29,015,653 | 77,603 | |||
Line of Credit | 2014 Term Loan | |||||
Long-Term Debt | |||||
Debt financing | $ 27,000,000 | ||||
Debt financing costs | 100,000 | $ 300,000 | |||
Reimbursal for debt financing costs | $ 200,000 | ||||
Effective interest rate (as a percent) | 10.20% | ||||
Interest expense | $ 300,000 | $ 400,000 | |||
Line of Credit | 2014 Term Loan, First Tranche | |||||
Long-Term Debt | |||||
Outstanding borrowings | $ 13,900,000 | $ 14,300,000 | |||
Hercules | 2014 Term Loan | Common Stock | |||||
Long-Term Debt | |||||
Exercisable amount (in shares) | 73,725 | ||||
Exercisable warrants equal to common stock, value | $ 607,500 | ||||
Exercise price of warrant (in dollars per share) | $ 8.24 | ||||
Equity Rights Letter Agreement | Hercules | |||||
Long-Term Debt | |||||
Issuance of common stock | $ 2,000,000 | ||||
Right to participate in subsequent financings, amount | 2,000,000 | ||||
Financing costs allocated to APIC | $ 36,000 | ||||
Common Stock | Equity Rights Letter Agreement | Hercules | |||||
Long-Term Debt | |||||
Issuance of common stock (in shares) | 223,463 | ||||
Issuance of common stock | $ 2,000,000 | ||||
Subsequent Event | Line of Credit | 2018 Term Loan | |||||
Long-Term Debt | |||||
Debt financing | $ 14,000,000 | ||||
Interest rate (as a percent) | 7.75% | ||||
Prepayment, written notice period (in days) | 7 years | ||||
Prepayment charge, first twelve months (as a percent) | 3.00% | ||||
Prepayment charge, between twelve months and twenty four months (as a percent) | 2.00% | ||||
Prepayment charge, after twenty four months (as a percent) | 1.00% | ||||
Additional end of term charge (as a percent) | 6.70% | ||||
Attachment or judgment on the Company's assets | $ 100,000 | ||||
Default involving indebtedness, minimum | $ 100,000 | ||||
Subsequent Event | Line of Credit | 2018 Term Loan | Prime rate | |||||
Long-Term Debt | |||||
Variable rate (as a percent) | 7.75% | ||||
Spread on variable rate basis (as a percent) | 5.00% | ||||
Subsequent Event | Line of Credit | 2014 Term Loan | |||||
Long-Term Debt | |||||
End of term charge (as a percent) | 4.95% | ||||
Subsequent Event | Hercules | 2018 Term Loan | Common Stock | |||||
Long-Term Debt | |||||
Exercisable amount (in shares) | 329,411 |
Long-term debt - Schedule of fu
Long-term debt - Schedule of future principal payments (Details) - 2014 Term Loan - Line of Credit $ in Thousands | Mar. 31, 2018USD ($) |
2,018 | $ 3,309 |
2,019 | 10,848 |
Total | $ 14,157 |
Commitments and contingencies -
Commitments and contingencies - Schedule of future minimum lease payments (Details) $ in Thousands | Mar. 31, 2018USD ($) |
Commitments and Contingencies Disclosure [Abstract] | |
2,018 | $ 1,209 |
2,019 | 1,637 |
2,020 | 274 |
Total | $ 3,120 |
Commitments and contingencies33
Commitments and contingencies - Narrative (Details) - USD ($) $ in Thousands | 1 Months Ended | |||
Aug. 31, 2016 | May 31, 2016 | Mar. 31, 2018 | Dec. 31, 2017 | |
Commitments and contingencies | ||||
Renewal term | 3 years | 3 years | ||
Master Facilities Lease 2012 | ||||
Commitments and contingencies | ||||
Outstanding letter of credit | $ 316 | $ 316 |
Stockholders' equity - Narrativ
Stockholders' equity - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands | Feb. 21, 2018 | Jan. 17, 2018 | Jan. 31, 2018 | Mar. 31, 2018 | Mar. 31, 2017 | May 09, 2018 | Jan. 19, 2018 | Jan. 01, 2018 | Dec. 31, 2017 | May 08, 2015 | Mar. 02, 2015 |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||
Common stock authorized (in shares) | 175,000,000 | ||||||||||
Par value (in dollars per share) | $ 0.001 | ||||||||||
Preferred stock authorized (in shares) | 25,000,000 | ||||||||||
Preferred stock par value (in dollars per share) | $ 0.001 | ||||||||||
Common stock issued (in shares) | 83,057,643 | 28,734,898 | |||||||||
Preferred stock issued (in shares) | 1,635 | 0 | |||||||||
Common stock outstanding (in shares) | 83,057,643 | 28,734,898 | |||||||||
Preferred stock outstanding (in shares) | 1,635 | 0 | |||||||||
Proceeds from issuance of common stock | $ 52,538 | $ 246 | |||||||||
Beneficial conversion feature | 300 | ||||||||||
Change in fair value | $ 1,600 | ||||||||||
Payment of Financing and Stock Issuance Costs | $ 4,000 | ||||||||||
Payments of issuance costs | 2,600 | ||||||||||
Payments for warrant issuance | $ 1,400 | ||||||||||
Warrants to purchase Common Stock | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||
Warrants to purchase common stock (in shares) | 29,015,653 | 77,603 | |||||||||
Common stock reserved for issuance upon exercise of warrants | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||
Warrants to purchase common stock (in shares) | 28,938,050 | ||||||||||
Warrants to purchase common stock in periods prior to the IPO | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||
Warrants to purchase common stock (in shares) | 3,878 | ||||||||||
Hercules | Common stock reserved for issuance upon exercise of warrants | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||
Warrants to purchase common stock (in shares) | 73,725 | ||||||||||
At-the-market equity offering program | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||
Offering amount (up to) | $ 50,000 | $ 40,000 | |||||||||
Subsequent Event | Common Stock | At-the-market equity offering program | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||
Issuance of common stock (in shares) | 3,700,000 | ||||||||||
Proceeds from issuance of common stock | $ 4,000 | ||||||||||
Underwritten Public Offering [Member] | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||
Exercise price of warrant (in dollars per share) | $ 1.20 | ||||||||||
Underwritten Public Offering [Member] | Common Stock | Concurrent Offerings | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||
Warrants to purchase common stock (in shares) | 26,682,500 | ||||||||||
Issuance of common stock (in shares) | 53,365,000 | ||||||||||
Underwritten Public Offering [Member] | Common Stock | Over-Allotment Option [Member] | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||
Warrants to purchase common stock (in shares) | 957,745 | 8,004,750 | 1,438,050 | ||||||||
Sale of Stock, Consideration Received on Transaction | $ 1,000 | ||||||||||
Underwritten Public Offering [Member] | Common Stock | Additional Overallotment Option [Member] | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||
Warrants to purchase common stock (in shares) | 4,002,375 | ||||||||||
Underwritten Public Offering [Member] | Convertible Preferred Stock | Concurrent Offerings | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||
Preferred stock par value (in dollars per share) | $ 0.001 | ||||||||||
Preferred stock issued (in shares) | 1,635 | ||||||||||
Warrants to purchase common stock (in shares) | 817,500 | ||||||||||
Sale of Stock, Consideration Received on Transaction | $ 1,600 | ||||||||||
Shares issued upon conversion (in shares) | 1,635,000 | ||||||||||
Underwritten Public Offering [Member] | Common Class A [Member] | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||
Par value (in dollars per share) | $ 0.001 | ||||||||||
Share Price (in dollars per share) | $ 1 | ||||||||||
Sale of Stock, Consideration Received on Transaction | $ 53,400 | ||||||||||
Ownership threshold | 9.99% | ||||||||||
Shares issued upon conversion (in shares) | 1,000 | ||||||||||
Warrants | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||
Share Price (in dollars per share) | $ 0.89 | $ 1.05 | |||||||||
Warrants | (Level 3) | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||
Issuance of Warrants | $ 21,414 | $ 18,231 | |||||||||
Change in fair value | 3,183 | ||||||||||
Overallotment Option | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||
Issuance of Warrants | 0 | $ 2,441 | |||||||||
Exercise of Overallotment Option | $ 877 |
Stock and employee benefit pl35
Stock and employee benefit plans - Schedule of stock-based compensation expense for stock options granted to employees and non-employees (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | |
Stock Based Compensation Expense | ||
Total | $ 644 | $ 1,021 |
Research and development | ||
Stock Based Compensation Expense | ||
Total | 141 | 387 |
General and administrative | ||
Stock Based Compensation Expense | ||
Total | $ 503 | $ 634 |
Stock and employee benefit pl36
Stock and employee benefit plans - Schedule of stock option activity for employees and nonemployees (Details) - Stock options - USD ($) $ / shares in Units, shares in Thousands | 3 Months Ended | ||
Mar. 31, 2018 | Mar. 31, 2017 | Dec. 31, 2017 | |
Shares | |||
Outstanding at the beginning of the period (in shares) | 4,129 | ||
Granted (in shares) | 1,826 | ||
Exercised (in shares) | 0 | ||
Canceled (in shares) | (763) | ||
Outstanding at the end of the period (in shares) | 5,192 | ||
Exercisable at the end of the period (in shares) | 2,478 | ||
Vested or expected to vest at the end of the period (in shares) | 5,192 | ||
Weighted- Average Exercise Price | |||
Outstanding at the beginning of the period (in dollars per share) | $ 5.48 | ||
Granted (in dollars per share) | 1 | ||
Exercised (in dollars per share) | 0 | ||
Canceled (in dollars per share) | 3.95 | ||
Outstanding at the end of the period (in dollars per share) | 4.13 | ||
Exercisable at the end of the period (in dollars per share) | 5.88 | ||
Vested or expected to vest at the end of the period (in dollars per share) | $ 4.13 | ||
Weighted- Average Remaining Contractual Term (years) | |||
Outstanding at the beginning/end of the period | 6 years 9 months 18 days | 7 years 26 days | |
Exercisable at the end of the period | 4 years 6 months 7 days | ||
Vested or expected to vest at the end of the period | 6 years 9 months 18 days | ||
Aggregate Intrinsic Value | |||
Outstanding at the end of the period (in dollars) | $ 97 | $ 0 | |
Exercisable at the end of the period (in dollars) | 2 | ||
Vested or expected to vest at the end of the period (in dollars) | $ 97 |
Stock and employee benefit pl37
Stock and employee benefit plans - Narrative (Details) - USD ($) $ in Thousands | 1 Months Ended | 3 Months Ended | 4 Months Ended | ||
Mar. 31, 2018 | May 31, 2017 | Mar. 31, 2018 | Mar. 31, 2017 | Sep. 30, 2017 | |
Stock option activity for employees and nonemployees | |||||
Total | $ 644 | $ 1,021 | |||
RSUs | 2014 ESPP | |||||
Stock option activity for employees and nonemployees | |||||
Granted (in shares) | 47,620 | ||||
Units of RSUs vested immediately (in shares) | 7,937 | ||||
RSUs vesting in the future (in shares) | 23,810 | ||||
Remaining RSUs to vest | 15,873 | ||||
Canceled (in shares) | (23,810) | ||||
Performance-based stock options | |||||
Stock option activity for employees and nonemployees | |||||
Options outstanding (in shares) | 56,336 | 56,336 | |||
Outstanding ESPP | 2014 ESPP | |||||
Stock option activity for employees and nonemployees | |||||
Number of shares of common stock authorized under the plan | 200,776 | 200,776 | |||
Shares remaining for future issuance (in shares) | 7 | 7 | |||
Total | $ 11 | $ 38 |
Restructuring costs - Narrative
Restructuring costs - Narrative (Details) | Mar. 31, 2018 |
Strategic alternatives for GEN-003 | |
Restructuring Cost and Reserve [Line Items] | |
Reduction to workforce (as a percent) | 40.00% |
Restructuring costs - Summary o
Restructuring costs - Summary of restructuring activities (Details) - Strategic alternatives for GEN-003 - USD ($) $ in Thousands | 3 Months Ended | 4 Months Ended |
Mar. 31, 2018 | Dec. 31, 2017 | |
Restructuring Cost and Reserve [Line Items] | ||
Charges incurred during the year ended December 31, 2017 | $ 2,618 | |
Amount paid through period | $ (540) | (1,050) |
Less non-cash charges during the year ended December 31, 2017 | (1,028) | |
Remaining liability | 0 | 540 |
Employee severance, benefits and related costs | ||
Restructuring Cost and Reserve [Line Items] | ||
Charges incurred during the year ended December 31, 2017 | 1,064 | |
Amount paid through period | (14) | (1,050) |
Less non-cash charges during the year ended December 31, 2017 | 0 | |
Remaining liability | 0 | 14 |
Contract terminations | ||
Restructuring Cost and Reserve [Line Items] | ||
Charges incurred during the year ended December 31, 2017 | 526 | |
Amount paid through period | (526) | |
Less non-cash charges during the year ended December 31, 2017 | ||
Remaining liability | 0 | 526 |
Asset impairments | ||
Restructuring Cost and Reserve [Line Items] | ||
Charges incurred during the year ended December 31, 2017 | 1,028 | |
Amount paid through period | 0 | 0 |
Less non-cash charges during the year ended December 31, 2017 | (1,028) | |
Remaining liability | $ 0 | $ 0 |
Net loss per share attributab40
Net loss per share attributable to common stockholders (Details) - shares shares in Thousands | 3 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | |
Common stock equivalents, presented on an as converted basis, were excluded from the calculation of net loss per share for the periods presented, due to their anti-dilutive effect | ||
Common stock equivalents (in shares) | 34,208 | 5,070 |
Stock options | ||
Common stock equivalents, presented on an as converted basis, were excluded from the calculation of net loss per share for the periods presented, due to their anti-dilutive effect | ||
Common stock equivalents (in shares) | 5,192 | 4,968 |
Warrants | ||
Common stock equivalents, presented on an as converted basis, were excluded from the calculation of net loss per share for the periods presented, due to their anti-dilutive effect | ||
Common stock equivalents (in shares) | 29,016 | 78 |
Outstanding ESPP | ||
Common stock equivalents, presented on an as converted basis, were excluded from the calculation of net loss per share for the periods presented, due to their anti-dilutive effect | ||
Common stock equivalents (in shares) | 0 | 24 |